drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Humanized IgG1 monoclonal antibody targeting HER2; binds extracellular domain IV to inhibit HER2 signaling, promote receptor internalization, reduce ectodomain shedding, and induce Fc-mediated ADCC.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting HER2 (ERBB2) extracellular domain IV; inhibits HER2 signaling, promotes receptor internalization, reduces ectodomain shedding, and engages Fcγ receptors to induce antibody-dependent cell-mediated cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT05786716